Accepted Manuscript

Acceptability of randomization to levonorgestrel versus copper intrauterine device among women requesting IUD insertion for contraception

Sharon L. Achilles, Beatrice A. Chen, Jessica K. Lee, Aileen M. Gariepy, Mitchell D. Creinin

PII: S0010-7824(15)00544-2

DOI: doi: 10.1016/j.contraception.2015.08.009

Reference: CON 8593

To appear in: Contraception

Received date: 10 June 2015 Revised date: 7 August 2015 Accepted date: 13 August 2015



Please cite this article as: Achilles Sharon L., Chen Beatrice A., Lee Jessica K., Gariepy Aileen M., Creinin Mitchell D., Acceptability of randomization to levonorgestrel versus copper intrauterine device among women requesting IUD insertion for contraception, *Contraception* (2015), doi: 10.1016/j.contraception.2015.08.009

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Acceptability of randomization to levonorgestrel versus copper intrauterine device among

women requesting IUD insertion for contraception

Sharon L. Achilles^a, Beatrice A. Chen^a, Jessica K. Lee^a, Aileen M. Gariepy^{a,1}, Mitchell D.

Creinin^{a,b,2}

^a Department of Obstetrics, Gynecology, and Reproductive Sciences and Center for Family

Planning Research, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 15213

^b Department of Epidemiology, University of Pittsburgh Graduate School of Public Health,

Pittsburgh, PA, USA 15213

Corresponding author: Sharon L. Achilles, MD, PhD, University of Pittsburgh, Department of

Obstetrics, Gynecology and Reproductive Sciences, 300 Halket Street, Pittsburgh, PA 15213,

Telephone (412) 641-1403, Facsimile (412) 641-1133, email achisx@upmc.edu.

Conflicts of interest: Dr. Creinin is a consultant for Merck, Actavis, Bayer, Danco, Teva and

Polkadoc. The Department of Obstetrics and Gynecology at the University of California, Davis

receives funding for contraceptive research from Merck and Medicines 360. The Department of

Obstetrics, Gynecology and Reproductive Sciences at the University of Pittsburgh receives

research funding from Medicines 360, Bayer and Agile Therapeutics. The remaining authors

report no conflicts of interest.

Word count abstract: 100

¹ Dr. Gariepy's current affiliation is the Department of Obstetrics and Gynecology, Yale University, New Haven, CT, USA 06520

² Dr. Creinin's current affiliation is the Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, CA, USA 95817

Download English Version:

https://daneshyari.com/en/article/6171177

Download Persian Version:

https://daneshyari.com/article/6171177

Daneshyari.com